Molina Arturo MD's Form 4 filing
Protagonist Therapeutics, IncPTGX · filed Mar 14, 2025
- Accession no.
- 0001104659-25-024063
- Filed
- Mar 14, 2025
- Trade date
- Mar 13, 2025
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.70M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Molina Arturo MDCIK 0001398940 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2025 | Common Stock | MOption exerciseAcquired | +28,437 | $23.42 | +$665,994.54 | 112,329 | Direct | |
| Mar 13, 2025 | Common Stock | MOption exerciseAcquired | +2,077 | $38.98 | +$80,961.46 | 114,406 | Direct | |
| Mar 13, 2025 | Common Stock | SSaleDisposed | −30,514 | $55.74F1 | −$1,700,850.36 | 83,892 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2025 | Common Stock | MOption exerciseDisposed | −28,437 | $0.00 | $0 | 69,063 | Direct | |
| Mar 13, 2025 | Common Stock | MOption exerciseDisposed | −2,077 | $0.00 | $0 | 47,785 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.245 to $56.06. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.